Skip to main content
Premium Trial:

Request an Annual Quote

The BioCommerce Week Index: Apr 28, 2005

BioCommerce Week’s Index to the
Diversified Molecular Biology Tools Companies
Company
Ticker
Current Price
(
April 26, 2005)
Last Price
(
April 19, 2005)
% Change
Agilent
A
21.34
20.77
2.74
Applied Biosystems
ABI
20.19
20.28
-0.44
BD
BDX
56.55
56.71
-0.28
Beckman
BEC
66.34
66.29
0.08
Bio-Rad
BIO
49.21
50.06
-1.70
Bruker
BRKR
3.16
3.4
-7.06
GE
GE
36.18
36
0.50
Harvard Bio
HBIO
3.8
3.65
4.11
Invitrogen
IVGN
73.51
70.93
3.64
Molecular Devices
MDCC
18.6
19.54
-4.81
PerkinElmer
PKI
19.87
19.6
1.38
Sigma
SIAL
57.6
58.49
-1.52
Stratagene
STGN
8.11
8.01
1.25
Thermo
TMO
25.21
24.77
1.78
Waters
WAT
39
34.87
11.84
Index Average
33.24
32.89
1.04

 

Waters Shares Gain 12 Percent as Index Rebounds

In advance of its earnings report this week, Waters shares soared and the company regained approximately $384 million of the $1.2 billion in market share it lost in early April when it revised its earnings and revenue forecast downwards.

Waters shares closed up 12 percent to $39 for the five-day period ending Tuesday to lead the multiplatform molecular biology tools companies whose shares are tracked in the BioCommerce Week index. Waters this week reported 3-percent growth in revenues for its first quarter (see related story).

Overall, the BCW index closed up for only the second time in the last seven weeks, ending the period up 1 percent at $33.24 and outperforming the major stock-market indices. The Dow Jones Index and the S&P 500 finished even for the five-day period after rallying from a 2 percent retreat last week, while the Nasdaq was down approximately 0.75 percent. The Amex pharma index fell nearly 1 percent.

File Attachments
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.